Skip to main content
Retour
Watch Compare

Rein Therapeutics, Inc.

Qualité des données : 100%
RNTX
NASDAQ Manufacturing Chemicals
1,78 €
▲ 0,15 € (9,20%)
6 months return
—
Momentum
Neutral
ROE
-105,88%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-105,88%
En dessous de la moyenne du secteur (-54,47%)
ROIC-81,84%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,90
Interest CoverageN/A

Valorisation

PE (TTM)
-0,84
Au-dessus de la moyenne du secteur (-1,49)
P/B Ratio0,90
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -19,36 M

Price History

Tendances Financières

Objectif de Cours des Analystes

1 analyste
Buy
+461.8%
upside to target
Actuel
1,78 €
Consensus Target
10,00 €
10,00 €
Bas
10,00 €
Haut
Prévisions
BPA Prévisionnel
-1,33 €
CA Est.
0,0

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,49 € · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -0,25 € -0,28 € -0,21 € -1,22 € — —
Estimate -0,21 € -0,22 € -0,24 € -0,22 € -0,49 € -0,49 €
Surprise -19,05% -27,27% +12,50% -467,44% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -105,88% · Net Margin: N/A
Revenue (TTM) 0,0 Net Income (TTM) -49,87 M
ROE -105,88% ROA -89,71%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -19,36 M
ROIC -81,84% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0,90
Debt / Equity N/A Current Ratio 0,90
Interest Coverage N/A Asset Turnover 0,00
Working Capital -570 000 Tangible Book Value -2,34 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,84 · EV/EBITDA: N/A
P/E Ratio -0,84 Forward P/E N/A
P/B Ratio 0,90 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -46,34%
Market Cap 41,78 M Enterprise Value 37,73 M

Per Share

EPS: -1,96 · FCF/Share: -0,69
EPS (Diluted TTM) -1,96 Revenue / Share 0,00
FCF / Share -0,69 OCF / Share -0,69
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 38,82% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 38,82%
SBC-Adj. FCF -21,84 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -49,87 M -62,88 M -15,73 M -27,33 M -26,16 M
EPS (Diluted) -1,96 -3,51 -3,42 -6,02 —
Gross Profit — — — — —
Operating Income -50,63 M -65,11 M -16,28 M -27,65 M -26,61 M
EBITDA — — — — —
R&D Expenses 11,03 M 14,25 M 3,99 M 17,97 M 17,01 M
SG&A Expenses — — — — —
D&A 1 000,0 63 000,0 119 000,0 169 000,0 121 000,0
Interest Expense — — — — —
Income Tax -712 000,0 -1,54 M 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 24,16 M 62,19 M 106,01 M 22,01 M 48,48 M
Total Liabilities 7,24 M 7,80 M 7,71 M 3,38 M 4,58 M
Shareholders' Equity 16,92 M 54,39 M 6,89 M 18,62 M 43,90 M
Total Debt — — — — —
Cash & Equivalents 3,22 M 12,87 M 17,31 M 5,19 M 3,60 M
Current Assets 4,33 M 13,66 M 18,27 M 21,87 M 48,18 M
Current Liabilities 6,18 M 5,75 M 4,39 M 3,38 M 4,51 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -0,8 -1,5
P/B 0,9 1,6
ROE % -105,9 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3